Clinical Trial Update: Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin [Phase 2]

View source ↗

Summary

A Phase 2 study evaluated BMS-650032 in combination with peginterferon alfa-2a and ribavirin for hepatitis C. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BMS-650032
• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus | Phase 2 | Status: COMPLETED